Core Viewpoint - The company, YaoYigou, reported its first half-year loss since going public, with a revenue of 2.157 billion yuan, a slight decrease of 3.06% year-on-year, and a net profit attributable to shareholders of -7.6144 million yuan, a significant decline of 162.95% [1][4]. Group 1: Business Performance - The traditional business of YaoYigou, primarily focused on pharmaceutical distribution and agency, saw revenue declines of 9.86% and 6.37% in its two main segments, leading to an overall drop of 8.27% in digital pharmaceutical distribution to 1.92 billion yuan [1][2]. - The new business segment, which includes self-produced pharmaceuticals and brand operations, experienced a remarkable revenue growth of 104.74%, with a gross margin of 53.11%, but this segment only contributed 8.53% to total revenue [2][3]. - The ToB digital distribution business, which holds the highest revenue share, grew by 42.9% in 2024 but saw a decline of 3.34% in the first half of this year to 1.15 billion yuan [3]. Group 2: Financial Metrics - Sales expenses increased by 46% to 164 million yuan, attributed to rapid growth in e-commerce business and increased online promotion costs [3]. - Management expenses rose by 6.94% due to an expanded business scope, leading to higher employee compensation [3]. - Financial expenses increased by 12.72% due to a decline in deposit interest rates [3]. Group 3: Leadership Changes - The founder, Li Yanfei, stepped down as chairman, with Chen Shunjun taking over as chairman and general manager, aiming to drive the digital transformation of the company [5][6]. - Chen Shunjun has a background in artificial intelligence and big data, and is expected to integrate these technologies into the pharmaceutical distribution industry [5][6]. - Following the leadership change, the company announced the establishment of a new subsidiary focused on AI and digital supply chain integration [5].
药易购现上市以来半年报首亏,新帅上任能否力挽狂澜?